Investing2h
Madrigal Pharma stock jumps on positive trial results and revenue beat
Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...
Zacks.com on MSN10h
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...
BioPharma Dive10h
AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch
The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...
Targeted Oncology10h
FDA Accepts Odronextamab BLA in Relapsed/Refractory Follicular Lymphoma
The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...
Madrigal Pharmaceuticals Phase 3 data ‘encouraging,’ says UBS
Madrigal Pharmaceuticals (MDGL) reported Q4 results and provided a 2-year update from the open-label metabolic dysfunction-associated ...
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...
Madrigal reports ‘positive’ results from Phase 3 MAESTRO-NAFLD-1 trial
Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...